Skip to main content

Table 1 Description of study endpoints and associated risk score, CV ASPIRE study, Europe, 2011

From: Smoking cessation and the risk of cardiovascular disease outcomes predicted from established risk scores: Results of the Cardiovascular Risk Assessment among Smokers in Primary Care in Europe (CV-ASPIRE) Study

Risk score

Study endpoint

Study population

Study sample size

Risk period

Predictors

SCOREa

Cardiovascular Mortality Risk

Smokers attending primary care in Europe; age 39 to 91 years.

1419

10 years

Age, gender, systolic blood pressure, total cholesterol

Framinghamb

Coronary Heart Disease Risk

Smokers attending primary care in Europe; age 39 to 74 years.

1275

10 years

Age, gender, diabetes status, systolic and diastolic blood pressure, total cholesterol, LDL cholesterol

Framinghamc

Cardiovascular Disease Risk

Smokers attending primary care in Europe; age 39 to 91 years.

1368

10 years

Age, gender, diabetes status, systolic blood pressure, treatment of hypertension, total cholesterol, LDL and HDL cholesterol

Framinghamd

Hard Coronary Heart Disease Risk

Smokers attending primary care in Europe; age 39 to 79 years.

1372

10 years

Age, gender, systolic blood pressure, treatment of hypertension, total cholesterol, HDL cholesterol

Framinghame

Intermittent Claudication Risk

Smokers attending primary care in Europe; age 45 to 84 years.

1161

4 years

Age, gender, systolic blood pressure, treatment of hypertension, total cholesterol, coronary heart disease, number of cigarettes smoked per day

Framinghamf

Recurring Coronary Heart Disease Risk

Female smokers attending primary care in Europe; age 39 to 74 years, with history of coronary heart disease.

68

2 years

Age, gender, diabetes status, systolic blood pressure, fasting total cholesterol, fasting HDL cholesterol

Progetto CUOREg

Risk of Coronary or Cardiovascular Event

Smokers attending primary care in Europe; age 39 to 69 years.

1117

10 years

Age, gender, diabetes status, systolic blood pressure, total cholesterol, HDL cholesterol, treatment of hypertension

  1. References:
  2. a: Conroy RM, Pyörälä K, Fitzgerald AP, et al., SCORE project group. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 2003; 24(11):987–1003.
  3. b: Wilson PW, D'Agostino RB, Levy D, et al. Prediction of coronary heart disease using risk factor categories. Circulation 1998;97(18):1837–1847.
  4. c: D'Agostino RB, Sr., Vasan RS, Pencina MJ, et al. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation 2008; 117:743 753.
  5. d:. D'Agostino RB, Sr., Grundy S, Sullivan LM, et al. Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation. JAMA 2001; 286(2):180–187.
  6. e: Murabito JM, D'Agostino RB, Silbershatz H, et al. Intermittent claudication. A risk profile from the Framingham Heart Study. Circulation 1997;96(1):44–49.
  7. f: D'Agostino RB, Russell MW, Huse DM, et al. Primary and subsequent coronary risk appraisal: new results from the Framingham Study. Am Heart J 2000;139(2 Pt 1):272–281.
  8. g: Palmieri L, Panico S, Vanuzzo D, et al. La valutazione del rischio cardiovascolare globale assoluto: il punteggio individuale del Progetto CUORE. Annali dellIstituto superiore di sanita 2004:40(4):393–399.
Back to article page

BMC Public Health

ISSN: 1471-2458

Contact us